Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Next Previous
Trial Profile

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-BAFF receptor CAR T cell therapy (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors PeproMene Bio

Most Recent Events

  • 28 May 2026 According to a PeproMene Bio media release, trial is actively enrolling patients into expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL).
  • 28 May 2026 Results presented in a PeproMene Bio Media Release.
  • 28 May 2026 According to a PeproMene Bio media release, updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01 have been selected for an oral presentation at the 2026 Congress of the European Hematology Association (EHA).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top